Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • ACE-083: Phase I started

    Acceleron Pharma Inc. (NASDAQ:XLRN), Cambridge, Mass. Product: ACE-083 Business: Musculoskeletal Molecular target: Myostatin (GDF8) (MSTN) Description: Ligand trap inhibiting myostatin and activins Indication: Increase …

    Published on 10/20/2014
  • BLZ-100: Phase Ib started

    Blaze Bioscience Inc., Seattle, Wash. Product: BLZ-100 (formerly CyTP 007) Business: Diagnostic Molecular target: NA Description: Combination of an optimized peptide and a near-infrared beacon Indication: Detect and …

    Published on 10/20/2014
  • Cenicriviroc: Phase IIb started

    Tobira Therapeutics Inc., San Francisco, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Cenicriviroc (formerly TBR-652) Business: Hepatic Molecular target: CC chemokine receptor 5 (CCR5) (…

    Published on 10/20/2014
  • FDX104: Phase II started

    Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), Rehovot, Israel Product: FDX104 Business: Dermatology Molecular target: NA Description: Topical foam formulation of doxycycline Indication: Prevent EGFR inhibitor skin toxicity…

    Published on 10/20/2014
  • Human neural stem cells: Phase I started

    Neuralstem Inc. (NYSE-M:CUR), Rockville, Md. Product: Human neural stem cells (hNSCs) (NSI-566, NSI-566RSC) Business: Neurology Molecular target: Not applicable Description: Human neural stem cells (hNSCs) Indication: …

    Published on 10/20/2014
  • Human neural stem cells: Phase II started

    StemCells Inc. (NASDAQ:STEM), Newark, Calif. Product: Human neural stem cells (HuCNS-SC) Business: Neurology Molecular target: Not applicable Description: Purified human neural stem cells Indication: Treat cervical …

    Published on 10/20/2014
  • LentiGlobin BB305 gene therapy: Phase I started

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Product: LentiGlobin BB305 gene therapy Business: Hematology Molecular target: NA Description: Autologous CD34+ stem cells transduced ex vivo with a lentiviral vector …

    Published on 10/20/2014
  • Mibefradil dihydrochloride: Phase Ib started

    Cavion LLC, Charlottesville, Va. Product: Mibefradil dihydrochloride Business: Cancer Molecular target: Calcium channel T-type Description: T-type calcium channel blocker Indication: Treat recurrent glioblastoma …

    Published on 10/20/2014
  • Mipsagargin: Completed Phase II enrollment

    GenSpera Inc. (OTCBB:GNSZ), San Antonio, Texas Product: Mipsagargin (G-202) Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Prodrug of plant-derived cytotoxin …

    Published on 10/20/2014
  • OTO-104: Phase II/III started

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: OTO-104 Business: Other Molecular target: NA Description: Sustained-release dexamethasone gel delivered via intratympanic injection Indication: Treat acute hearing …

    Published on 10/20/2014
  • Rotavirus vaccine: Phase III started

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Rotavirus vaccine Business: Infectious Molecular target: NA Description: Oral, live attenuated tetravalent rotavirus vaccine against serotypes G1, G2, G3 and G4 …

    Published on 10/20/2014
  • SD-101: Phase I/II started

    Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Product: SD-101 Business: Cancer Molecular target: Toll-like receptor 9 (TLR9) Description: Immunostimulatory sequence (ISS)-based second-generation type C toll…

    Published on 10/20/2014
  • ShK-186: Phase Ib started

    Airmid Inc., Redwood City, Calif. Kineta Inc., Seattle, Wash. Product: ShK-186 Business: Autoimmune Molecular target: Potassium channel Kv1.3 (KCNA3) Description: Synthetic peptide that inhibits potassium channel Kv1.3…

    Published on 10/20/2014
  • Simeprevir: Phase II started

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Simeprevir (Sovriad, Galexos, Olysio) (TMC435) (formerly TMC435350) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 10/20/2014
  • VAL201: Phase I/II start

    ValiRx plc (LSE:VAL), London, U.K. Cancer Research UK, London, U.K. Product: VAL201 Business: Cancer Molecular target: Src Description: Src inhibitor Indication: Treat prostate cancer Endpoint: Safety Status: Phase I/II…

    Published on 10/20/2014
  • VSV-EBOV: Phase I started

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Product: VSV-EBOV Business: Infectious Molecular target: NA Description: Recombinant vesicular stomatitis virus (rVSV) vaccine expressing an Ebola virus protein …

    Published on 10/20/2014
  • XOMA 358: Phase I started

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Product: XOMA 358 Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Allosteric human mAb that binds to insulin receptor (INSR) Indication: …

    Published on 10/20/2014
  • Zybrestat fosbretabulin: Phase Ib/II started

    OxiGene Inc. (NASDAQ:OXGN), South San Francisco, Calif. Product: Zybrestat fosbretabulin (Combretastatin A4P) Business: Cancer Molecular target: Tubulin Description: A4 prodrug phosphatase-activated tumor vascular …

    Published on 10/20/2014
  • 18-methoxycoronaridine: Phase I started

    Hebron Farmaceutica S.A, Caruaru, Brazil Savant HWP Inc., San Carlos, Calif. Product: 18-methoxycoronaridine (18-MC) Business: Infectious Molecular target: Nicotinic acetylcholine receptor alpha(3)beta(4) Description: …

    Published on 10/13/2014
  • AeroVanc: Completed Phase II enrollment

    Savara Inc., Austin, Texas Product: AeroVanc (SAV005) Business: Infectious Molecular target: NA Description: Inhaled dry powder formulation of vancomycin in a capsule-based inhaler Indication: Treat methicillin-…

    Published on 10/13/2014
  • ALN-AS1: Clinical trial started

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Product: ALN-AS1 Business: Endocrine/Metabolic Molecular target: Aminolevulinate synthase-1 (ALAS-1) Description: Subcutaneous RNAi therapeutic targeting …

    Published on 10/13/2014
  • Arzerra ofatumumab: Phase III started

    Genmab A/S (CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Arzerra ofatumumab (HuMax-CD20) Business: Autoimmune Molecular target: CD20 Description: Human mAb …

    Published on 10/13/2014
  • Dexamethasone-loaded punctum plug: Completed Phase III enrollment

    Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Dexamethasone-loaded punctum plug (OTX-DP) Business: Neurology Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained- and …

    Published on 10/13/2014
  • Estradiol VagiCap: Phase III started

    TherapeuticsMD Inc. (NYSE-M:TXMD), Boca Raton, Fla. Product: Estradiol VagiCap (TX-004HR) (formerly TX 12-004-HR) Business: Endocrine/Metabolic Molecular target: NA Description: 17-beta estradiol using a VagiCap softgel…

    Published on 10/13/2014
  • Gevokizumab: Phase III started

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Servier, Neuilly-sur-Seine, France Product: Gevokizumab (S 78989, XOMA 052) Business: Inflammation Molecular target: Interleukin-1 (IL-1) beta Description: Humanized IgG2 mAb …

    Published on 10/13/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993